Market Research Logo

Pharmerging Markets 2016-2020

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Global pharmaceuticals market
    • Market size and forecast
      • Table Global pharmaceuticals market 2015-2020 ($ billions)
      • Table Drivers, challenges, and trends in global pharmaceuticals market
  • Pharmerging markets
    • Table Share of pharmerging markets in global pharmaceuticals market 2015
  • Market landscape
    • Market size and forecast
      • Table Pharmerging markets 2015-2020 ($ billions)
      • Table Shares of pharmerging markets in global pharmaceuticals market 2015-2020
      • Table Shares of Tier I, II, and III countries in pharmerging markets 2015-2020
      • Table Pharmerging market shares by country 2015
      • Table Shares of pharmerging markets in global pharmaceuticals market 2015 and 2020
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation based on geography
    • Table Pharmerging markets by geography
  • Market overview of Tier I countries
    • Table Tier I: Geographical representation
    • China
      • Table Major therapy areas by drug sales 2015
      • Table Pharmaceuticals market in China 2015-2020 ($ billions)
      • Table Pharmaceuticals market in China: SWOT analysis
  • Market overview of Tier II countries
    • Table Geographic representation of Tier II countries
    • Table Pharmaceuticals market in Tier II countries 2015-2020 ($ billions)
    • Brazil
      • Table Pharmaceuticals market in Brazil 2015-2020 ($ billions)
      • Table Pharmaceuticals market in Brazil: SWOT analysis
    • Russia
      • Table Pharmaceuticals market in Russia 2015-2020 ($ billions)
      • Table Pharmaceuticals market in Russia: SWOT analysis
    • India
      • Table Major therapy areas by drug sales 2015
      • Table Major acquisitions in pharmaceuticals sector in India
      • Table Pharmaceuticals market in India 2015-2020 ($ billions)
      • Table Pharmaceuticals market in India: SWOT analysis
  • Market overview of Tier III countries
    • Table Geographic representation of Tier III countries
    • Market size and forecast
      • Table Pharmaceuticals market in Tier III countries 2015-2020 ($ billions)
      • Table Revenue for select Tier III countries 2015 ($ billions)
      • Table Tier III countries' pharmaceuticals market: SWOT analysis
  • Market drivers
    • Social and private health insurance
    • Increase in healthcare spending
    • High incidence of diseases
    • Impact of patent cliff on mature markets
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Affordability and access
    • High competition
    • Partial regulatory policies
    • Price pressure
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Strategic alliances
    • Increase in generic sales
    • Mergers and acquisitions
    • Early drug launches in pharmerging markets
  • Vendor landscape
    • Competitive scenario
    • AstraZeneca
      • Table AstraZeneca: Business segmentation based on revenue 2014
      • Table AstraZeneca: Business segmentation based on revenue 2013 and 2014 ($ billions)
      • Table AstraZeneca: Geographical segmentation based on revenue 2014
      • Table AstraZeneca: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
      • Table AstraZeneca: SWOT analysis
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Business segmentation based on revenue 2014
      • Table GlaxoSmithKline: Business segmentation based on revenue 2013 and 2014 ($ billions)
      • Table GlaxoSmithKline: Geographical segmentation based on revenue 2014
      • Table GlaxoSmithKline: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
      • Table GlaxoSmithKline: SWOT analysis
    • Merck
      • Table Merck: Business segmentation based on revenue 2014
      • Table Merck: Business segmentation based on revenue 2013 and 2014 ($ billions)
      • Table Merck: Geographical segmentation based on revenue 2014
      • Table Merck: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
      • Table Merck: SWOT analysis
    • Novartis
      • Table Novartis: Business segmentation based on revenue 2014
      • Table Novartis: Business segmentation based on revenue 2013 and 2014 ($ billions)
      • Table Novartis: Geographical segmentation based on revenue 2014
      • Table Novartis: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ millions)
      • Table Novartis :SWOT analysis
    • Pfizer
      • Table Pfizer: Business segmentation based on revenue 2014
      • Table Pfizer: Business segmentation based on revenue 2013 and 2014 ($ billions)
      • Table Pfizer: Geographical segmentation based on revenue 2014
      • Table Pfizer: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
      • Table Pfizer: SWOT analysis
    • Sanofi
      • Table Sanofi: Business segmentation based on revenue 2014
      • Table Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Sanofi: Geographical segmentation based on revenue 2014
      • Table Sanofi: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
      • Table Sanofi: SWOT analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Pharmerging Markets 2016-2020

Market outlook of the pharmerging markets

Technavios research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets

Tier I countries (China)
Tier II countries (Brazil, India, and Russia)
Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)
The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors

The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -

AstraZeneca
GlaxoSmithKline
Merck
Novartis
Pfizer
Sanofi
Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include

What will the market size and the growth rate be in 2020
What are the key factors driving the pharmerging markets
What are the key market trends impacting the growth of the pharmerging markets
What are the challenges to market growth
Who are the key vendors in this market space
What are the market opportunities and threats faced by the vendors in the pharmerging markets
Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
What are the key outcomes of the five forces analysis of the pharmerging markets
Technavio also offers customization on reports based on specific client requirement.

Related reports:

Global Pharmaceutical Packaging Market 2015-2019
Global Active Pharmaceutical Ingredients Market 2015-2019
Global Pharmaceuticals Wholesale and Distribution Market 2015-2019
Pharmaceutical Packaging Market in Europe 2015-2019
Pharmaceutical Packaging Market in North America 2015-2019
Pharmaceutical Logistics Market in the APAC 2015-2019
Active Pharmaceutical Ingredients (API) Market in India 2015-2019


Press Release

Technavio Announces the Publication of its Research Report Pharmerging Market 2016-2020
Technavio recognizes the following companies as the key players in the Pharmerging Market: AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer and Sanofi
Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.
Commenting on the report, an analyst from Technavios team said: Pharmerging countries mostly include developing or less-developed countries where the affordability of drugs plays a major role for the blossoming of the market. Hence, the utilization and sale of generic drugs are high. Though the sales of generics have slowed down, the sales still outpace the sales of originator molecules. Also, pharmaceutical companies such as Pfizer and Sanofi are showing an interest toward the development of generics for attaining considerable shares in the pharmerging markets.
According to the report, public and private healthcare insurance are among the major drivers influencing the growth of this market. The governments of pharmerging countries such as India have implemented schemes that can be availed by eligible patients to obtain free treatment for diseases.
Further, the report states that poor access to and affordability of drugs challenge pharmerging markets.

Companies Mentioned

AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, Valeant Pharmaceuticals.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;